WO2001008659A1 - Pharmaceutical compositions for topical application to treat erectile dysfunction - Google Patents

Pharmaceutical compositions for topical application to treat erectile dysfunction Download PDF

Info

Publication number
WO2001008659A1
WO2001008659A1 PCT/CA2000/000799 CA0000799W WO0108659A1 WO 2001008659 A1 WO2001008659 A1 WO 2001008659A1 CA 0000799 W CA0000799 W CA 0000799W WO 0108659 A1 WO0108659 A1 WO 0108659A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostaglandin
phentolamine
pharmaceutical composition
papaverine
providing
Prior art date
Application number
PCT/CA2000/000799
Other languages
French (fr)
Inventor
J. Simon Mcgrail
Ara G. Keresteci
Barry Kasman
Original Assignee
Lakefield Minerals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakefield Minerals Ltd. filed Critical Lakefield Minerals Ltd.
Priority to AU59576/00A priority Critical patent/AU5957600A/en
Publication of WO2001008659A1 publication Critical patent/WO2001008659A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Definitions

  • the invention relates to pharmaceutical preparations for treating erectile dysfunction.
  • Male impotency or erectile dysfunction is a problem affecting millions of men across North America and the rest of the world. Up to thirty million men are affected by male impotency in the United States alone. The problem is especially common in aging men. There are several treatments available for this condition.
  • External vacuum therapies are available for treating all types of impotence. This is often used as a first step treatment for erectile dysfunction. Generally, this therapy involves the creation of negative pressure in a plastic cylinder through the use of a pump. The user inserts his penis into the cylinder. The vacuum causes blood to enter the penis in a way similar to a natural erection. Despite the fact that this therapy has a ninety percent success rate, it is an awkward and uncomfortable treatment. Because of these drawbacks, men are often reluctant to use this treatment.
  • Erectile dysfunction can also be treated through oral prescription medication.
  • ViagraTM received FDA approval on March 27, 1998 and has received much publicity since being introduced into the marketplace ViagraTM can be taken orally in a pill form This treatment has had a good success rate in treating impotent men
  • urethral suppository Another method for treating erectile dysfunction is the use of a urethral suppository This procedure involves the insertion of an applicator tip into the urethra for delivery of a suppository Absorption occurs through the urethral wall This treatment is quite awkward, uncomfortable, and often painful
  • More radical treatments for erectile dysfunction include penile implant surgery and vascular surgery This is a last resort because of the inherent risks of undertaking any surgical procedure It has been known since the early nineteen eighties that penile injection therapy is effective for creating erections Three drugs, papavenne, phentolamine and prostaglandin E1 have been used successfully to create erections through this technique
  • the patient must inject a solution containing one or more of these drugs directly into the penis Hand pressure must be applied afterwards for a few minutes to prevent bleeding
  • Penile injection therapy Another drawback of penile injection therapy is p ⁇ apism This is an unwanted prolonged erection that results from injecting more of the drug than is required for an erection of normal duration Penile injection therapy also has a drawback of being extremely costly Injections normally cost about twenty to twenty-five dollars
  • a pharmaceutical preparation that can be applied topically to the penis would avoid the drawbacks of the current treatments for erectile dysfunction
  • a topical treatment has not been previously developed because there has previously not been a known carrier for drugs such as papavenne, phentolamine and prostaglandin E1 that can both be absorbed through the skin into the bloodstream while effectively carrying the drugs into the bloodstream
  • drugs such as papavenne, phentolamine and prostaglandin E1 that can both be absorbed through the skin into the bloodstream while effectively carrying the drugs into the bloodstream
  • the invention comprises a pharmaceutical composition that is effective for treating erectile dysfunction through topical application to the penis.
  • the pharmaceutical composition includes at least one compound that is effective for creating an erection when entering the bloodstream of the penis and a suitable penetrant carrier to enhance absorption of the compound.
  • composition for topical application to treat erectile dysfunction.
  • the composition includes at least one of the following compounds:
  • a suitable penetrant carrier to enhance absorption of at least one of these compounds is also provided.
  • a pharmaceutical composition for topical application to treat erectile dysfunction includes at least one compound that is effective in creating erections in impotent men upon entering the bloodstream of the penis.
  • the compound is dissolved in dimethyl sulfoxide (DMSO).
  • a method of making a pharmaceutical composition for topical application to treat erectile dysfunction comprises the steps of providing a quantity of at least one compound that creates an erection upon entering the bloodstream of the penis, mixing at least one compound in a volume of water, providing a volume of DMSO and mixing the compound /water mixture in the DMSO.
  • a method for making a pharmaceutical composition for topical application to treat erectile dysfunction comprises the steps of providing a quantity of papaverine, providing a quantity of phentolamine, providing a quantity of prostaglandin E1 , mixing the papaverine, phentolamine and prostaglandin E1 in a quantity of water to create a solution, providing a quantity of a suitable penetrant carrier to enhance absorption of the papaverine, phentolamine and prostaglandin E1 and mixing the solution in the suitable penetrant carrier.
  • a method of making a pharmaceutical composition for topical application to treat erectile dysfunction comprises the steps of providing a quantity of papaverine, providing a quantity of phentolamine, providing a quantity of prostaglandin E1 , mixing the papaverine, phentolamine and prostaglandin E1 in a quantity of water to create a solution, providing a quantity of DMSO and mixing the solution in the DMSO.
  • a method of making a pharmaceutical composition for topical application to treat erectile dysfunction is provided.
  • the method comprises the steps of providing a quantity of papaverine, providing a quantity of phentolamine, providing a quantity of prostaglandin E1 , providing a quantity of DMSO and mixing the papaverine, phentolamine and prostaglandin E1 in the DMSO.
  • composition for topical application to treat erectile dysfunction.
  • the composition includes at least one of the following compounds:
  • a pharmaceutical composition has at least one pharmaceutical that enlarges blood vessels.
  • the pharmaceutical is dissolved in DMSO.
  • the pharmaceutical composition of the present invention is prepared by mixing an effective amount of papaverine, phentolamine and prostaglandin E1 into a quantity of water sufficient to dissolve these compounds.
  • the solution is then mixed with preferably an equal volume of dimethyl sulfoxide (DMSO). It is not strictly necessary that the volume should be equal but this is preferred for ease of preparation.
  • DMSO dimethyl sulfoxide
  • the resulting mixture is then applied directly onto the penis.
  • the DMSO acts as a carrier for the papaverine, phentolomine and prostaglandin E1 as the DMSO is absorbed through the skin of the penis into the blood vessels of the penis. Once these compounds reach the blood vessels of the penis, an erection is achieved rapidly by the user.
  • An effective topical preparation may also be prepared by dissolving papaverine, phentolomine and prostaglandin E1 directly into DMSO. The solution is then applied directly to the penis resulting in rapid erection.
  • compositions containing one or more of papaverine, phentolamine or prostaglandin E1 mixed with an effective penetrant carrier other than DMSO such as a cream are within the scope of the present invention.
  • Example 1 Preparation of water/DMSQ formulation.
  • solution A The compounds above are mixed into approximately 4 milliliters of water to produce solution A.
  • Solution A is then mixed into approximately four milliliters of DMSO to produce solution B.
  • the resulting solution B is appropriate and effective for a single topical application to create an erection.
  • Prostaglandin E1 100 micrograms
  • the compounds above are mixed into 4 milliliters of DMSO.
  • the resulting mixture is appropriate and effective for a single topical application to create erection.
  • the mixtures of example 1 and example 2 are effective for rapidly producing high quality erections of normal duration.

Abstract

A pharmaceutical composition for topical application to treat erectile dysfunction is provided. The composition includes at least one of the following compounds: paparevine, phentolamine and prostaglandin E1. The compounds are mixed with dimethyl sulfoxide (DMSO) which acts as a suitable penetrant carrier to enhance absorption of the compounds. The pharmaceutical composition is effective for creating erections of normal duration through topical application.

Description

Pharmaceutical Compositions for Topical Application to Treat Erectile Dysfunction
Field of the Invention
The invention relates to pharmaceutical preparations for treating erectile dysfunction.
Background
Male impotency or erectile dysfunction is a problem affecting millions of men across North America and the rest of the world. Up to thirty million men are affected by male impotency in the United States alone. The problem is especially common in aging men. There are several treatments available for this condition.
External vacuum therapies are available for treating all types of impotence. This is often used as a first step treatment for erectile dysfunction. Generally, this therapy involves the creation of negative pressure in a plastic cylinder through the use of a pump. The user inserts his penis into the cylinder. The vacuum causes blood to enter the penis in a way similar to a natural erection. Despite the fact that this therapy has a ninety percent success rate, it is an awkward and uncomfortable treatment. Because of these drawbacks, men are often reluctant to use this treatment.
Erectile dysfunction can also be treated through oral prescription medication.
The best known is Sildenafil Citrate (Viagra™). Viagra™ received FDA approval on March 27, 1998 and has received much publicity since being introduced into the marketplace Viagra™ can be taken orally in a pill form This treatment has had a good success rate in treating impotent men
However, many men are reluctant to try this treatment The consistent use of a pill is considered to be undesirable by many men since the drug enters the user's entire system The drug is therefore circulated through the user's entire body and is not concentrated in the affected region This is a concern because it is still unknown what the long-term effects of Viagra™ may be on other organs and organ systems of the body
Hormone therapy is used to treat impotence caused by a testosterone deficiency Raising the level of testosterone in men having a deficiency has proved to be effective for treating impotency in many cases This treatment has the drawback of having serious side effects
Another method for treating erectile dysfunction is the use of a urethral suppository This procedure involves the insertion of an applicator tip into the urethra for delivery of a suppository Absorption occurs through the urethral wall This treatment is quite awkward, uncomfortable, and often painful
More radical treatments for erectile dysfunction include penile implant surgery and vascular surgery This is a last resort because of the inherent risks of undertaking any surgical procedure It has been known since the early nineteen eighties that penile injection therapy is effective for creating erections Three drugs, papavenne, phentolamine and prostaglandin E1 have been used successfully to create erections through this technique
The patient must inject a solution containing one or more of these drugs directly into the penis Hand pressure must be applied afterwards for a few minutes to prevent bleeding
Despite the fact that impotent men have enjoyed a high success rate through this treatment, the method has several obvious drawbacks The prospect of injecting a needle into the penis is quite daunting to many men The puncture of the needle can also cause a great deal of pain As a result, few choose this method when presented with other alternatives
Another drawback of penile injection therapy is pπapism This is an unwanted prolonged erection that results from injecting more of the drug than is required for an erection of normal duration Penile injection therapy also has a drawback of being extremely costly Injections normally cost about twenty to twenty-five dollars
A pharmaceutical preparation that can be applied topically to the penis would avoid the drawbacks of the current treatments for erectile dysfunction A topical treatment has not been previously developed because there has previously not been a known carrier for drugs such as papavenne, phentolamine and prostaglandin E1 that can both be absorbed through the skin into the bloodstream while effectively carrying the drugs into the bloodstream There is therefore a need for a pharmaceutical preparation that is effective for creating an erection in impotent men through topical application to the penis.
Summary of the Invention
The invention comprises a pharmaceutical composition that is effective for treating erectile dysfunction through topical application to the penis. The pharmaceutical composition includes at least one compound that is effective for creating an erection when entering the bloodstream of the penis and a suitable penetrant carrier to enhance absorption of the compound.
According to one aspect of the invention a pharmaceutical composition for topical application to treat erectile dysfunction is provided. The composition includes at least one of the following compounds:
■ Papaverine
■ Phentolamine
■ Prostaglandin E1.
A suitable penetrant carrier to enhance absorption of at least one of these compounds is also provided.
According to another aspect of the invention a pharmaceutical composition for topical application to treat erectile dysfunction is provided. The composition includes at least one compound that is effective in creating erections in impotent men upon entering the bloodstream of the penis. The compound is dissolved in dimethyl sulfoxide (DMSO).
According to another aspect of the invention a method of making a pharmaceutical composition for topical application to treat erectile dysfunction is provided. The method comprises the steps of providing a quantity of at least one compound that creates an erection upon entering the bloodstream of the penis, mixing at least one compound in a volume of water, providing a volume of DMSO and mixing the compound /water mixture in the DMSO.
According to yet another aspect of the present invention, a method for making a pharmaceutical composition for topical application to treat erectile dysfunction is provided. The method comprises the steps of providing a quantity of papaverine, providing a quantity of phentolamine, providing a quantity of prostaglandin E1 , mixing the papaverine, phentolamine and prostaglandin E1 in a quantity of water to create a solution, providing a quantity of a suitable penetrant carrier to enhance absorption of the papaverine, phentolamine and prostaglandin E1 and mixing the solution in the suitable penetrant carrier.
According to another aspect of the present invention, a method of making a pharmaceutical composition for topical application to treat erectile dysfunction is provided. The method comprises the steps of providing a quantity of papaverine, providing a quantity of phentolamine, providing a quantity of prostaglandin E1 , mixing the papaverine, phentolamine and prostaglandin E1 in a quantity of water to create a solution, providing a quantity of DMSO and mixing the solution in the DMSO. According to another aspect of the present invention, a method of making a pharmaceutical composition for topical application to treat erectile dysfunction is provided. The method comprises the steps of providing a quantity of papaverine, providing a quantity of phentolamine, providing a quantity of prostaglandin E1 , providing a quantity of DMSO and mixing the papaverine, phentolamine and prostaglandin E1 in the DMSO.
According to another aspect of the present invention, use is made of the pharmaceutical composition for topical application to treat erectile dysfunction. The composition includes at least one of the following compounds:
■ Papaverine
■ Phentolamine
■ Prostaglandin E1 ,
and a suitable penetrant carrier to enhance absorption of said at least one compound.
According to yet another aspect of the present invention, use is made of a pharmaceutical preparation to topically treat male impotency. A pharmaceutical composition has at least one pharmaceutical that enlarges blood vessels. The pharmaceutical is dissolved in DMSO. Description
The pharmaceutical composition of the present invention is prepared by mixing an effective amount of papaverine, phentolamine and prostaglandin E1 into a quantity of water sufficient to dissolve these compounds. The solution is then mixed with preferably an equal volume of dimethyl sulfoxide (DMSO). It is not strictly necessary that the volume should be equal but this is preferred for ease of preparation. The resulting mixture is then applied directly onto the penis. The DMSO acts as a carrier for the papaverine, phentolomine and prostaglandin E1 as the DMSO is absorbed through the skin of the penis into the blood vessels of the penis. Once these compounds reach the blood vessels of the penis, an erection is achieved rapidly by the user.
It is also possible two prepare a pharmaceutical composition that is effective for creating an erection in this manner, that includes only one or two of the three drugs mentioned above.
An effective topical preparation may also be prepared by dissolving papaverine, phentolomine and prostaglandin E1 directly into DMSO. The solution is then applied directly to the penis resulting in rapid erection.
It is preferred to mix all three drugs together with DMSO. However, it is also possible to prepare a composition containing either one or two of the three drugs mixed with DMSO. Positive results are achieved with these formulations but the best results are achieved when all three drugs are mixed together. Compositions containing one or more of papaverine, phentolamine or prostaglandin E1 mixed with an effective penetrant carrier other than DMSO such as a cream are within the scope of the present invention.
The following examples illustrate the invention:
Example 1 : Preparation of water/DMSQ formulation.
Papaverine: 300 milligrams Phentolamine: 15 milligrams Prostaglandin E1 : 100 micrograms
The compounds above are mixed into approximately 4 milliliters of water to produce solution A. Solution A is then mixed into approximately four milliliters of DMSO to produce solution B. The resulting solution B is appropriate and effective for a single topical application to create an erection.
Example 2: Preparation of pure DMSO mixture.
Papaverine: 300 milligrams Phentolamine: 15 milligrams
Prostaglandin E1 : 100 micrograms,
The compounds above are mixed into 4 milliliters of DMSO. The resulting mixture is appropriate and effective for a single topical application to create erection. The mixtures of example 1 and example 2 are effective for rapidly producing high quality erections of normal duration.
Although the invention has been described with preferred embodiments, it is to be understood that modifications may be resorted to as will be apparent to those skilled in the art. Such modifications and variations are to be considered within the purview and scope of the present invention.

Claims

ClaimsWe claim:
1. A pharmaceutical composition for topical application to treat erectile dysfunction, the composition including at least one of the following compounds:
• Papaverine
• Phentolamine
• Prostaglandin E1 ,
and a suitable penetrant carrier to enhance absorption of said at least one compound.
2. A pharmaceutical composition according to claim 1 wherein the penetrant carrier is dimethyl sulfoxide (DMSO).
3. A pharmaceutical composition according to claim 2 wherein the composition includes papaverine and prostaglandin E1.
4. A pharmaceutical composition according to claim 2 wherein the composition includes papaverine and phentolamine.
5. A pharmaceutical composition according to claim 2 wherein the composition includes prostaglandin E1 and phentolamine.
6. A pharmaceutical composition according to claim 2 wherein the composition includes papaverine, phentolamine and prostaglandin E1.
7. A pharmaceutical composition for topical application to treat erectile dysfunction, the composition including at least one compound that is effective for producing an erection upon entry into the bloodstream of the penis, dissolved in dimethyl sulfoxide (DMSO).
8. A pharmaceutical composition according to claim 7 wherein the at least one compound is selected from the group comprising papaverine, phentolamine and prostaglandin E1.
A pharmaceutical composition according to claim 7 wherein the at least one compound includes papaverine and prostaglandin E1.
10. A pharmaceutical composition according to claim 7 wherein the at least one pharmaceutical includes papaverine and phentolamine.
11. A pharmaceutical according to claim 7 wherein the at least one pharmaceutical includes phentolamine and prostaglandin E1
12. A pharmaceutical composition according to claim 7 wherein the at least one compound includes papaverine, phentolamine and prostaglandin E1.
13. A method of making a pharmaceutical composition for topical application to treat erectile dysfunction comprising the steps of:
• providing a quantity of at least one compound that is effective for producing an erection upon entry into the bloodstream of the penis;
• mixing said at least one compound in a volume of water;
• providing a volume of DMSO; and
• mixing the compound/water mixture in said DMSO.
14. A method according to claim 13 wherein the at least the compound includes papaverine, phentolamine and prostaglandin E1.
15. A method of making a pharmaceutical composition for topical application to treat erectile dysfunction comprising the steps of:
• Providing a quantity of papaverine;
• Providing a quantity of phentolamine;
• Providing a quantity of prostaglandin E1 ;
• Mixing the papaverine, phentolamine and prostaglandin E1 in a quantity of water;
• Providing a quantity of a suitable penetrant carrier to enhance absorption of said papaverine, phentolamine and prostaglandin E1 ; and
• Mixing the solution in said suitable penetrant carrier.
16. A method according to claim 16 wherein the suitable penetrant carrier is DMSO.
17. A method of making a pharmaceutical composition for topical application to treat erectile dysfunction comprising the steps of:
• Providing a quantity of papaverine;
• Providing a quantity of phentolamine;
• Providing a quantity of prostaglandin E1 ;
• Mixing the papaverine, phentolamine and prostaglandin E1 in a quantity of water to create a solution;
• Providing a quantity of DMSO; and
• Mixing the solution in said DMSO.
18. A method of making a pharmaceutical composition for topical application to treat erectile dysfunction comprising the steps of:
Providing a quantity of papaverine;
Providing a quantity of phentolamine;
Providing a quantity of prostaglandin E1 ;
Providing a quantity of DMSO; and
Mixing the papaverine, phentolamine and prostaglandin E1 in said DMSO.
19. Use of the pharmaceutical composition of claim 1 to topically treat erectile dysfunction.
20. Use of the pharmaceutical composition of claim 7 to topically treat erectile dysfunction.
PCT/CA2000/000799 1999-07-30 2000-07-05 Pharmaceutical compositions for topical application to treat erectile dysfunction WO2001008659A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59576/00A AU5957600A (en) 1999-07-30 2000-07-05 Pharmaceutical compositions for topical application to treat erectile dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36504899A 1999-07-30 1999-07-30
US09/365,048 1999-07-30

Publications (1)

Publication Number Publication Date
WO2001008659A1 true WO2001008659A1 (en) 2001-02-08

Family

ID=23437266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000799 WO2001008659A1 (en) 1999-07-30 2000-07-05 Pharmaceutical compositions for topical application to treat erectile dysfunction

Country Status (2)

Country Link
AU (1) AU5957600A (en)
WO (1) WO2001008659A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677335B1 (en) 1999-10-11 2004-01-13 Pfizer Inc Pharmaceutically active compounds
WO2004011029A2 (en) * 2002-07-26 2004-02-05 Adams Kenneth W Pharmaceutical compositions for penis enlargement
US8374577B2 (en) 2002-06-18 2013-02-12 Telefonaktiebolaget Lm Ericsson (Publ) Parallel coordinated operations in private domains

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
EP0346297A1 (en) * 1988-06-08 1989-12-13 CENTRO MEDICO HARVEY S.r.l. A preparation for topical use in the therapeutic treatment of impotentia coeundi
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
WO1998043614A1 (en) * 1997-03-28 1998-10-08 Lam Pharmaceuticals, Llc Drug preparations for treating sexual dysfunction
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
DE19728103A1 (en) * 1997-07-02 1999-01-07 Winfried Dr Med Heinicke Composition for treatment of erectile dysfunction
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6031002A (en) * 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
EP0346297A1 (en) * 1988-06-08 1989-12-13 CENTRO MEDICO HARVEY S.r.l. A preparation for topical use in the therapeutic treatment of impotentia coeundi
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
WO1998043614A1 (en) * 1997-03-28 1998-10-08 Lam Pharmaceuticals, Llc Drug preparations for treating sexual dysfunction
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
DE19728103A1 (en) * 1997-07-02 1999-01-07 Winfried Dr Med Heinicke Composition for treatment of erectile dysfunction
US6031002A (en) * 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677335B1 (en) 1999-10-11 2004-01-13 Pfizer Inc Pharmaceutically active compounds
US7176311B2 (en) 1999-10-11 2007-02-13 Pfizer Inc. Process for preparing pharmaceutically active compounds
US8374577B2 (en) 2002-06-18 2013-02-12 Telefonaktiebolaget Lm Ericsson (Publ) Parallel coordinated operations in private domains
WO2004011029A2 (en) * 2002-07-26 2004-02-05 Adams Kenneth W Pharmaceutical compositions for penis enlargement
WO2004011029A3 (en) * 2002-07-26 2004-05-21 Kenneth W Adams Pharmaceutical compositions for penis enlargement
US7671091B2 (en) 2002-07-26 2010-03-02 Adams Kenneth W Penis enlargement

Also Published As

Publication number Publication date
AU5957600A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
RU2331423C2 (en) Delivery system with controlled release for intranasal applying
EP0357581B1 (en) Composition for the treatment of erectile dysfunction
EP1322286B3 (en) Polymeric delivery formulations of leuprolide with improved efficacy
DE60112102T2 (en) COMBINATION OF A NO-DONOR AND ANTIOXIDANE FOR THE TREATMENT OF SEXUAL DISORDERS
US20050271597A1 (en) Prostate hypertrophy treatment composition and method
PL189436B1 (en) Composition for and method of treating penis erection disorders
EA000566B1 (en) A stable, uniform, nitroglycerin-based cream for topical use, the method of preparing the cream and the use of the cream for treating male erectile dysfunction or female anorgasmia or for treating microvascular diseases or wounds or surgical incisions
ZA200604683B (en) Pharmaceutical compositions and methods for insulin treatment
Walker et al. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex®)
Wolfson et al. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction
Karakousis et al. Modes of regional chemotherapy
JPH10158169A (en) Pharmaceutical preparation containing trospium chloride, its preparation and use thereof
US7513879B2 (en) Noninvasive angioplasty using momentary vacuum therapy
WO2001008659A1 (en) Pharmaceutical compositions for topical application to treat erectile dysfunction
JPH0840880A (en) Medicine on basis of ketoprofen in soft gelatin capsule medicine and its preparation
EP0618798B1 (en) Pyridylguanidine compounds for treatment of erectile dysfunction
MXPA04007828A (en) Prostaglandin composition for the treatment of erectile dysfunction.
RU2407519C2 (en) Composition for enhanced vessel wall smooth muscle relaxation
Ulm The treatment of primary priapism with arfonad
US20020094988A1 (en) Method of treating erectile dysfunction
RU2076644C1 (en) Method for treating hemangiomae
JPH0466847B2 (en)
CA2243657C (en) Compositions for treatment of erectile dysfunction
WO1998055076A2 (en) Preparation for topical application to the male sexual organ
KR20030005436A (en) Medical composition kit for treating lesioned abnormal tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP